Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development Journal Article
| Authors: | Kelloff, G. J.; Hoffman, J. M.; Johnson, B.; Scher, H. I.; Siegel, B. A.; Cheng, E. Y.; Cheson, B. D.; O'Shaughnessy, J.; Guyton, K. Z.; Mankoff, D. A.; Shankar, L.; Larson, S. M.; Sigman, C. C.; Schilsky, R. L.; Sullivan, D. C. |
| Article Title: | Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development |
| Abstract: | 2-[18F] Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamental property of neoplasia, the Warburg effect. This molecular imaging technique offers a complementary approach to anatomic imaging that is more sensitive and specific in certain cancers. FDG-PET has been widely applied in oncology primarily as a staging and restaging tool that can guide patient care. However, because it accurately detects recurrent or residual disease, FDG-PET also has significant potential for assessing therapy response. In this regard, it can improve patient management by identifying responders early, before tumor size is reduced; nonresponders could discontinue futile therapy. Moreover, a reduction in the FDG-PET signal within days or weeks of initiating therapy (e.g., in lymphoma, non-small cell lung, and esophageal cancer) significantly correlates with prolonged survival and other clinical end points now used in drug approvals. These findings suggest that FDG-PET could facilitate drug development as an early surrogate of clinical benefit. This article reviews the scientific basis of FDG-PET and its development and application as a valuable oncology imaging tool. Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed. Recommendations include initial validation against approved therapies, retrospective analyses to define the magnitude of change indicative of response, further prospective validation as a surrogate of clinical benefit, and application as a phase II/III trial end point to accelerate evaluation and approval of novel regimens and therapies. © 2005 American Association for Cancer Research. |
| Keywords: | survival analysis; review; erlotinib; cancer combination chemotherapy; cancer growth; drug efficacy; validation process; paclitaxel; cancer patient; topotecan; positron emission tomography; neoplasm staging; cancer grading; sensitivity and specificity; neoplasms; reproducibility of results; imatinib; melanoma; image analysis; lung non small cell cancer; diagnostic imaging; cetuximab; medical examination; colorectal carcinoma; sarcoma; cancer center; breast carcinoma; lymphoma; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; gefitinib; tipifarnib; ovary carcinoma; tamoxifen; lung carcinoma; glucose; thyroid carcinoma; trastuzumab; head and neck carcinoma; prostate carcinoma; glucose metabolism; lonafarnib |
| Journal Title: | Clinical Cancer Research |
| Volume: | 11 |
| Issue: | 8 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2005-04-15 |
| Start Page: | 2785 |
| End Page: | 2808 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-04-2626 |
| PUBMED: | 15837727 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 223" - "Export Date: 24 October 2012" - "CODEN: CCREF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work